双联和三联疗法时代的转移性激素敏感性前列腺癌。

IF 3.8 2区医学 Q2 ONCOLOGY Current Treatment Options in Oncology Pub Date : 2024-03-01 Epub Date: 2024-01-04 DOI:10.1007/s11864-023-01173-1

Anthony V Serritella, Maha Hussain

{"title":"双联和三联疗法时代的转移性激素敏感性前列腺癌。","authors":"Anthony V Serritella, Maha Hussain","doi":"10.1007/s11864-023-01173-1","DOIUrl":null,"url":null,"abstract":"Opinion statement: Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals of cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"293-312"},"PeriodicalIF":3.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.\",\"authors\":\"Anthony V Serritella, Maha Hussain\",\"doi\":\"10.1007/s11864-023-01173-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Opinion statement: Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals of cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.\",\"PeriodicalId\":50600,\"journal\":{\"name\":\"Current Treatment Options in Oncology\",\"volume\":\" \",\"pages\":\"293-312\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Treatment Options in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11864-023-01173-1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-023-01173-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

意见陈述：近年来，转移性激素敏感性前列腺癌的治疗发生了重大变化，总生存率大幅提高。男性的生存期比以往任何时候都要长，目前的中位生存期已接近 6 年。转移性疾病发生的时间和程度以及患者的个体因素有助于推荐双联疗法，包括雄激素剥夺（ADT）加化疗或雄激素受体信号抑制（ARSI），或ADT+ARSI+化疗的三联疗法。必须继续开发新的治疗方法，以提高生存率，实现治愈目标。更好的生物标志物可使治疗更有效，从而提高疾病控制率、生活质量和生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.

Opinion statement: Treatment for metastatic hormone-sensitive prostate cancer has undergone significant evolution in recent years, leading to substantial improvements in overall survival. Men are living longer than ever before with a median survival now which is almost 6 years. The timing and extent of metastatic disease combined with individual patient factors helps treatment recommendation of doublet therapy including androgen deprivation (ADT) plus either chemotherapy or androgen receptor signaling inhibition (ARSI) or triplet therapy with ADT+ARSI+chemotherapy. New treatments must continue to be developed to enhance survival with goals of cure. Better biomarkers that allow for more effective treatments will enhance disease control, quality of life, and survival.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.

期刊最新文献

New Therapeutic Targets in RAS Wild-type Pancreatic Cancer. Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease? Community Palliative Care: What are the Best Models? Contemporary Review of Adenocarcinoma of the Cervix. Updates in Treatment of HER2-positive Metastatic Breast Cancer.